Repligen (RGEN) Tops Q3 EPS by 10c ; Offers Guidance

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.43, $0.10 better than the analyst estimate of $0.33. Revenue for the quarter came in at $155 million versus the consensus estimate of $153.22 million.

GUIDANCE:

Repligen sees FY2024 EPS of $1.50-$1.58, versus the consensus of $1.49. Repligen sees FY2024 revenue of $630-639 million, versus the consensus of $629.7 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• JPMorgan Starts Nuvation Bio Inc (NUVB) at Overweight
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform